Articles & Video
Life Sciences in 2020: Predictions from industry insiders
Industry insiders predict how life sciences will change in 2020 in emerging therapies, clinical trials, regulations and agriculture.
The future of peptide vaccines and personalized peptide therapies - WHITEPAPER
This whitepaper explores the exciting potential future of peptide vaccines and personalized peptide therapies.
What is an oligonucleotide?
What is an oligonucleotide? Discover the different oligo classes and the future of oligonucleotide therapies.
Drug delivery trends in oligo, peptide, mRNA and CRISPR therapeutics
What are the current strategies and technology demands in delivering oligos, peptides mRNA and CRISPR therapeutics? We find out from our recent survey data.
What are peptides?
What are peptides? We look at the potential of the peptide in the beauty industry and in peptide therapeutics.
How oligonucleotide, peptide, CRISPR and mRNA companies are using collaboration to move forward
We examined recent survey data to explore how collaboration is used by oligonucleotide, peptide, CRISPR and mRNA companies throughout their supply chains.
REPORT: State of Oligo, Peptide, mRNA and CRISPR Therapeutics 2019
This exclusive report explores the state of the oligo, peptide, mRNA and CRISPR therapeutics industry in 2019 - download it here.
CMC approaches to accelerate peptide, oligonucleotides and mRNA therapeutics development - WHITEPAPER
This whitepaper explores the different CMC approaches to accelerate peptide, oligonucleotides and mRNA therapeutics development. Download it here.
Boosting commercialization of oligonucleotides as a raw materials supplier with Aldevron
Tom Lynch, Vice President of Sales & Client Development at Aldevron joined us at TIDES US in San Diego to discuss the company's role as a CDMO and how it is approaching the oligonucleotides market as a critical raw materials supplier.
ART BioScience’s mRNA-based treatment for Duchenne muscular dystrophy
Dr. Aleks Schein, Chief Scientific Officer at ART BioScience joined us to discuss its mRNA-based treatment for Duchenne muscular dystrophy and how the therapy could expand to other genetic disorders.
Collaborating to innovate: AstraZeneca's collaborations in mRNAs, antisense oligos and cell therapy
Anna Collén, Senior Project Director, Innovative Medicine at AstraZeneca, discusses how collaboration is driving innovation in mRNAs and antisense oligonucleotides at AZ.
Can GalNAc conjugated oligonucleotides still be improved?
GalNAc conjugated oligonucleotides: Marie Wikström Lindholm from Silence Therapeutics discusses how GalNAc conjugates can still be improved.
Drug Delivery of Oligonucleotides, Peptides, RNA, mRNA and CRISPR - WHITEPAPER
This whitepaper explores the latest innovations, strategies and challenges of drug delivery of oligonucleotides, peptides, RNA, mRNA and CRISPR. Download it here.
Oligo collaboration: The European Pharmaceutical Oligonucleotide Consortium
Oligo collaboration is essential for the development of new therapeutics. Rachel Orr from GSK, discusses the launch of the European Pharmaceutical Oligonucleotide Consortium (EPOC).
Oligo and Peptide Therapeutics 2018: State of the Industry Report
This exclusive report reveals unique insights into the state of the oligo and peptide therapeutics industry in 2018 based on the survey responses of 162 professionals.
Treating rare genetic disorders of obesity - Lex Van der Ploeg
Lex Van der Ploeg, PhD, CSO at Rhythm Pharmaceuticals, discusses rare genetic disorders of obesity, as well as some of the challenges currently facing the peptide and oligonucleotide therapy industry.
Challenging "wasteful time consuming optimization" when making a peptide - Michael Karney
Michael Karney, Life Science Product Manager at CEM, laments the wasteful, time consuming optimization involved in the current process of making a peptide and how that can be improved.
How the oligonucleotide and peptide industries are shifting - INDUSTRY VOICES
Oligonucleotide and peptide experts share insights on industry shifts, mRNA therapies and new discoveries.
Cell penetrating peptides, delivery strategies and working with commercial developers - Dr Dehua Pei, OSU
Interview - Dr Dehua Pei, Professor of Chemistry and Biochemistry at Ohio State University, discusses cell penetrating peptides, delivery strategies, and working with commercial developers of peptide and oligonucleotide therapeutics.
Launching clinical antisense oligonucleotide manufacturing capability in a biologics company
Dr Sheron Branham, Associate Director of Process Engineering and Manufacturing at Biogen, explores why they internalized a new manufacturing platform for antisense oligonucleotides.
The reluctance to technological growth in peptides - with Rodney Lax
Rodney Lax, PhD from PolyPeptide Group, explores the reluctance to technological change within the peptides industry.